Helus Pharma (HELP) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Helus Pharma (HELP) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 9.3% versus a loss of 24.6%. Over five years, MNPR leads with a +184.5% price change compared with -88.1% for HELP. Helus Pharma is the larger company by market cap ($487.7 million vs $467.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HELP | MNPR |
|---|---|---|
| Share price | $6.11 | $69.00 |
| Market cap | $487.68M | $467.60M |
| 1-day change | -9.88% | -1.84% |
| YTD return | -25.31% | +5.67% |
| 1-year return | +9.30% | -24.64% |
| 5-year return | -88.09% | +184.54% |
| EPS (TTM) | $-4.25 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-13.72M |
| 52-week high | $15.15 | $124.82 |
| 52-week low | $3.76 | $50.07 |
| Distance from 52-week high | -59.67% | -44.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +564.81% | +88.65% |
| Average volume | 1.83M | 151.83K |
| Shares outstanding | 79.81M | 6.78M |
| Employees | 100 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed MNPR by 33.9 percentage points over the past year.
About Helus Pharma
HELP stock →Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
HELP vs MNPR FAQ
Which is bigger, Helus Pharma or Monopar Therapeutics?
Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $467.60M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, HELP or MNPR?
HELP returned +9.30% over the past 12 months, compared with -24.64% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Helus Pharma and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.